View Webcasts

Moral Distress Part 1

Activity Details
  • Credit Amounts:
    • CME: 0.75
    • Other: 0.75
  • Cost: Free
  • Release: Jul 6, 2017
  • Expires: Jul 5, 2020
  • Estimated Time to Complete:
    45 Minutes
  • System Requirements:
  • Average User Rating:
    (6 Ratings)

Faculty

Maria C.  Clay Maria C. Clay, PhD
Chair and Professor, Bioethics and Interdisciplinary Studies
Brody School of Medicine
Adjunct Professor, Public Health
Director, Clinical Skills Assessment and Education
College of Education
East Carolina University
Greenville, North Carolina

Annette G.  Greer Annette G. Greer, PhD, MSN, RN
Associate Professor, Bioethics and Interdisciplinary Studies
East Carolina University School of Medicine
Greenville, North Carolina

M Sara Rosenthal M Sara Rosenthal, PhD
Professor and Founding Director, Program for Bioethics, Internal Medicine, Pediatrics and Behavioral Science
University of Kentucky College of Medicine
Chair, UK HealthCare Ethics Committee
Lexington, Kentucky

Needs Statement

Moral Distress is an "occupational hazard" for healthcare providers. It describes a situation in which the healthcare provider knows what the ethical/moral course of action is, but is constrained from acting on it. There may be legal, institutional, or social constraints, including patient/surrogate decisions. Moral distress is an integrity-compromising situation, and if unresolved, leads to moral residue, which can cause healthcare providers to have both physical and emotional symptoms. It is a leading cause of retention problems and workplace bullying in certain healthcare professions. This novel educational module and site  will review the definitions, causes, and consequences of moral distress, as well as offer some solutions.

Proper definitions of moral distress can improve inter-professional discussions about this phenomenon. Learn "what is moral distress", who is affected, and common situations that create it.

This activity has the same content as MORAL DISTRESS PART 1 that expired on June 30, 2017. If you participated in the original activity, please do not complete this release.

Target Audience

Physicians, Physician Assistants, Nurses, Nurse Practitioners, and Social Workers

Objectives

Upon completion of this educational activity, the participant will be able to:

1. Define moral distress and moral residue;
2. Recognize moral distress and moral residue;
3. Identify warning signs of moral distress;
4. Practice preventative ethics to reduce or avoid moral distress.

Accreditation

CME
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, UK Program for Bioethics, and East Carolina University. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies

  • Patient care

Other
UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

Faculty Disclosure

No speakers or planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky, UK Program for Bioethics, and East Carolina University.

Activity Faculty

Sara Rosenthal, Project Leader
Maria Clay, Associate Project Faculty
Annette Greer, Nursing Faculty

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.